IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-10-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-3382PMID 26500238PMCID PMC6437768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kineret®/IL-1ra Blocks the IL-1/IL-8 Inflammatory Cascade during Recombinant Panton Valentine Leukocidin-Triggered Pneumonia but Not during S. aureus Infection

  2014cited by this paper
• Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis

  2014cited by this paper
• Pancreatic Cancer Cells Isolated from Muc1-Null Tumors Favor the Generation of a Mature Less Suppressive MDSC Population

  2014cited by this paper
• KRAS: feeding pancreatic cancer proliferation.

  2014cited by this paper
• Pediatric Lung Transplantation

  2014cited by this paper
• An Undesired Effect of Chemotherapy

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Activation of nuclear factor-κB in acinar cells increases the severity of pancreatitis in mice.

  2013cited by this paper
• KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

  2012cited by this paper
• Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.

  2012cited by this paper
• Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.

  2012cited by this paper
• Pancreatic cancer: understanding and overcoming chemoresistance

  2011cited by this paper
• Therapeutic strategies for targeting ras proteins.

  2011cited by this paper
• Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

  2011cited by this paper
• Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

  2011cited by this paper
• Why not treat human cancer with interleukin-1 blockade?

  2010cited by this paper
• Secreted Interleukin-1α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of Nuclear Factor-κB

  2009cited by this paper
• NF-κB in carcinoma therapy and prevention

  2008cited by this paper
• NF-kappaB in carcinoma therapy and prevention.

  2008cited by this paper
• NF-κB as a target for cancer therapy

  2007cited by this paper
• NF-kappa B as a target for cancer therapy.

  2007cited by this paper
• Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells.

  2004cited by this paper
• Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1α in Induction of Constitutive NF-κB Activation in Pancreatic Cancer Cells*

  2004cited by this paper
• NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia

  2003cited by this paper
• NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.

  2003cited by this paper
• Immortalization with telomerase of the Nestin-positive cells of the human pancreas.

  2003cited by this paper
• Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex

  2000cited by this paper
• Progression model for pancreatic cancer.

  2000cited by this paper
• Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex.

  2000cited by this paper
• The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

  1999cited by this paper
• The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells

  1999cited by this paper
• Interleukin-1 receptor antagonist: role in biology.

  1998cited by this paper
• The Nuclear Factor-kB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells

  1998cited by this paper
• A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

  1991cited by this paper
• "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

  1981cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

  1966cited by this paper

• Obesity- and tumor-derived signals drive cancer-associated state transitions in breast mesenchymal stromal/stem cells reprogrammed by IL1RA or JAK inhibition

  2026cites this paper
• Proteomics in pancreatic cancer

  2025cites this paper
• Pharmacological Mechanisms of Berberine Against Triple Negative Breast Cancer: Integration of Network Pharmacology and Experimental Validation

  2025cites this paper
• Nucleus-translocated GCLM promotes chemoresistance in colorectal cancer through a moonlighting function

  2025cites this paper
• Targeting NLRP3 inflammasome activation in styrene-induced ototoxicity: comparative efficacy of rosmarinic acid and anakinra in mitigating oxidative and inflammatory damage.

  2025cites this paper
• Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma.

  2025cites this paper
• Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer

  2024cites this paper
• Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3

  2024cites this paper
• Exosomal lncRNA XIST promotes perineural invasion of pancreatic cancer cells via miR-211-5p/GDNF

  2024cites this paper
• Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment

  2024cites this paper
• Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment

  2024cites this paper
• Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer

  2024cites this paper
• Igniting hope: Harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy.

  2024cites this paper
• Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer

  2024cites this paper
• NLRP3 and cancer: Pathogenesis and therapeutic opportunities.

  2023cites this paper
• Interleukin-1 receptor antagonist: An alternative therapy for cancer treatment.

  2023cites this paper
• Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment

  2023cites this paper
• New insights into the role of adipocytes in pancreatic cancer progression: paving the way towards novel therapeutic targets

  2023cites this paper
• Cancer-associated fibroblasts: from basic science to anticancer therapy

  2023cites this paper
• A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma.

  2023cites this paper
• Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β

  2023cites this paper
• The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer

  2023cites this paper
• Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer.

  2023cites this paper
• The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis

  2023cites this paper
• Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship

  2023cites this paper
• The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma

  2022cites this paper
• The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma

  2022cites this paper
• Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer

  2022cites this paper
• Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment

  2022cites this paper
• Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy

  2022cites this paper
• Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients

  2022cites this paper
• Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• HOXA10 promote pancreatic cancer progression via directly activating canonical NF-κB signaling pathway.

  2022cites this paper
• The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.

  2022cites this paper
• Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer

  2022cites this paper
• The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?

  2021cites this paper
• Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma

  2021cites this paper
• Interleukin-1 signaling in solid organ malignancies.

  2021cites this paper
• First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

  2021cites this paper
• Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities

  2021cites this paper
• Dynamic roles of inflammasomes in inflammatory tumor microenvironment

  2021cites this paper
• Noise-Induced Cochlear Damage Involves PPAR Down-Regulation through the Interplay between Oxidative Stress and Inflammation

  2021cites this paper
• IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1

  2021cites this paper
• Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-κB-mediated-MAPK and NLRP3-caspase pathways.

  2021cites this paper
• The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective

  2020cites this paper
• Protein Signatures and Tissue Diagnosis of Pancreatic Cancer.

  2020cites this paper
• IL-1 Signaling in Tumor Microenvironment.

  2020cites this paper
• Recent progress in antitumor functions of the intracellular antibodies.

  2020cites this paper
• Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP

  2020cites this paper
• Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte–mediated immune suppression

  2020cites this paper
• DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS.

  2020cites this paper
• Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

  2020cites this paper
• TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations.

  2020cites this paper
• Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer

  2020cites this paper
• Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling

  2020cites this paper
• HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies

  2020cites this paper
• IL-1 and related cytokines in innate and adaptive immunity in health and disease

  2020cites this paper
• The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer

  2019cites this paper
• Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer

  2019cites this paper
• Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation

  2019cites this paper
• UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer.

  2019cites this paper
• Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies

  2019cites this paper
• Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

  2019cites this paper
• The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer

  2019cites this paper
• LATS1/2 suppress NFκB and aberrant EMT initiation to permit pancreatic progenitor differentiation

  2019cites this paper
• A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

  2019cites this paper
• Impact of Nuclear Interleukin-1 Alpha and EGFR Expression on Recurrence and Survival Outcomes in Oral Squamous Cell Carcinomas

  2019cites this paper
• Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells

  2019cites this paper
• Obesity-Induced Adipose Tissue Inflammation as a Strong Promotional Factor for Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• Quantitative assessment of extracellular IL-1 regulation.

  2019cites this paper
• NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB

  2019cites this paper
• Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

  2019cites this paper
• Uncoupling the Senescence-Associated Secretory Phenotype from Cell Cycle Exit via Interleukin-1 Inactivation Unveils Its Protumorigenic Role

  2019cites this paper
• Targeting liquid-liquid phase separation in pancreatic cancer

  2019cites this paper
• Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma

  2019cites this paper
• Innate immunity, inflammation and tumour progression: double‐edged swords

  2019cites this paper
• Two Birds with One Stone: Therapeutic Targeting of IL1α Signaling Pathways in Pancreatic Ductal Adenocarcinoma and the Cancer-Associated Fibroblasts.

  2019cites this paper
• IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

  2018cites this paper
• NF-κB in pancreatic cancer: Its key role in chemoresistance.

  2018cites this paper
• Interleukin-1α as an intracellular alarmin in cancer biology.

  2018cites this paper
• Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer.

  2018cites this paper
• Personalized disease signatures through information-theoretic compaction of big cancer data

  2018cites this paper
• Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition

  2018cites this paper
• Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation

  2018cites this paper
• Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.

  2018cites this paper
• Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion

  2018cites this paper
• Long‐term efficacy and safety of the interleukin‐1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma

  2017cites this paper
• The potential of targeting Sin3B and its associated complexes for cancer therapy

  2017cites this paper
• Inhibitor of Pancreatic Cancer by RHIL1RA—Letter

  2017cites this paper
• Targeting the Tumor Microenvironment by Intervention in Interleukin-1 Biology.

  2017cites this paper
• TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.

  2017cites this paper
• Immunotherapeutic approaches of IL‐1 neutralization in the tumor microenvironment

  2017cites this paper
• NFκB-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling

  2017cites this paper
• Correction: IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation

  2017cites this paper
• Inhibition of Pancreatic Cancer by RhIL1RA—Response

  2017cites this paper
• Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing

  2017cites this paper
• An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients

  2016cites this paper
• Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma

  2016cites this paper